BOSTON — Gastroesophageal reflux disease (GERD) is associated with better in-hospital outcomes for patients hospitalized with chronic obstructive pulmonary disease (COPD). The finding is a ...

Village Medical and The COPD Foundation today announced a webinar to support patients through Medicare Annual Enrollment ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

For the 16 million Americans with chronic obstructive pulmonary disease (COPD), travel can be as anxiety-provoking as it is life-affirming. The fatigue, chest tightness, congestion, and difficulty ...

With the label expansion, Dupixent becomes the first biologic treatment for COPD patients in the U.S. The IL-4 and IL-13 inhibitor is approved to be used as an add-on maintenance treatment by ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

The FDA approved dupilumab (Dupixent; Regeneron/Sanofi) today for treating patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 1 This approval ...

The company has said it expects the target COPD patient population eligible for the drug to be roughly 300,000 patients in the U.S. It has anticipated steeper growth in Dupixent sales in 2025 ...

The FDA decision, announced Friday, was based on a pair of late-stage trials that found Dupixent helped patients with the ... cleared for use in adults whose COPD symptoms aren’t under control ...

Study reveals that over 93% of primary care patients expect antibiotics ... of chronic obstructive pulmonary disease (COPD), and additional education about proper inhaler use is needed to improve ...

Objectives To examine current practices, attitudes and levels of confidence related to advance care planning (ACP) in patients with chronic obstructive pulmonary disease (COPD) among healthcare ...

Ohtuvayre is a selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, combining two properties in one medicine, which ultimately sets it apart in COPD for ...